Sacituzumab govitecan (SG), the first antibody–drug conjugate (ADC) approved for triple-
negative breast cancer, incorporates the anti-TROP2 antibody hRS7 conjugated to a …

Background The pivotal phase III ASCENT trial demonstrated improved survival outcomes
associated with sacituzumab govitecan (SG), an anti-trophoblast cell-surface antigen 2 (anti …

Sacituzumab govitecan (SG) is an anti-Trop-2 antibody-drug conjugate with an SN-38
payload. In the ASCENT study, patients with metastatic triple-negative breast cancer …

Purpose Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a
potential target for antibody-drug conjugates. Sacituzumab govitecan, an antibody-drug …

Objective: To review the pharmacology, efficacy, and safety of sacituzumab govitecan (-hziy;
IMMU-132, Trodelvy) for patients with metastatic triple-negative breast cancer (mTNBC) who …

Background Patients with metastatic triple-negative breast cancer have a poor prognosis.
Sacituzumab govitecan is an antibody–drug conjugate composed of an antibody targeting …

Purpose Sacituzumab govitecan (SG) is an antibody–drug conjugate composed of an anti–
Trop-2 antibody coupled to SN-38 via a proprietary hydrolyzable linker. In the ASCENT …

Background In pts with pretreated mTNBC, standard of care (SOC) chemotherapy is
associated with low objective response rates (ORRs) and short median progression-free …

Background Standard chemotherapy is associated with low response rates and short
progression-free survival among patients with pretreated metastatic triple-negative breast …

Introduction: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype
associated with an increased risk of recurrence and cancer-related death. Unlike hormone …